Andheri Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-06-2024
- Paid Up Capital ₹ 10.00 K
as on 20-06-2024
- Company Age 31 Year, 12 Days
- Last Filing with ROC 31 Mar 2020
- Revenue 26.67%
(FY 2015)
- Profit 44.91%
(FY 2015)
- Ebitda 37.70%
(FY 2015)
- Net Worth 7.09%
(FY 2015)
- Total Assets 7.86%
(FY 2015)
About Andheri Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Pharaoh Basta and Hufriz Basta serve as directors at the Company.
- CIN/LLPIN
U24230MH1993PTC075565
- Company No.
075565
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Dec 1993
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Andheri Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pharaoh Basta  | Director | 13-Dec-1993 | Current |
| Hufriz Basta | Director | 13-Dec-1993 | Current |
Financial Performance of Andheri Pharmaceuticals.
Andheri Pharmaceuticals Pvt Ltd, for the financial year ended 2015, experienced significant growth in revenue, with a 26.67% increase. The company also saw a substantial improvement in profitability, with a 44.91% increase in profit. The company's net worth moved up by a moderate rise of 7.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Andheri Pharmaceuticals?
In 2017, Andheri Pharmaceuticals had a promoter holding of 40.00% and a public holding of 60.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ghatkopar Homeopathic Pharmacy P LtdActive 30 years 8 months
Pharaoh Basta and Hufriz Basta are mutual person
- Fort Homeo Pharmacy Private LimitedActive 30 years 8 months
Pharaoh Basta and Hufriz Basta are mutual person
- Byculla Homeopathic Pharmacy P LtdActive 30 years 7 months
Pharaoh Basta and Hufriz Basta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Andheri Pharmaceuticals?
Unlock and access historical data on people associated with Andheri Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Andheri Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Andheri Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
